Liposome Lipid-Based Formulation Has the Least Influence on rAAV Transduction Compared to Other Transfection Agents

Abstract

Recombinant adeno-associated virus (rAAV) vectors are considered ideal vehicles for human gene therapy. Meanwhile, non-viral strategies, such as transfection agents (TAs), have also shown promise to deliver genetic materials, such as siRNA. Transduction with the rAAV vector is performed concurrently with transfection with plasmid DNA or RNA. In the present study, we report that various TAs inhibited rAAV-mediated transgene expression at diverse levels. Overall, cationic polymers and dendrimers dramatically blocked rAAV transduction, while lipid-based liposomes displayed the least effect. The inhibitory effect was dependent on the dose of TAs and the timing of infection, suggesting that the early stages of viral infection were involved. In addition, the present results indicate that the transgene expression of rAAV vectors was significantly increased by liposome-mediated transfection with adenoviral helper genes. At the same time, this was dramatically inhibited by liposome-mediated transfection with the trichosanthin gene encoding a type I ribosome-inactivating protein isolated from traditional Chinese medicine. Furthermore, liposomes also have little effect on rAAV-mediated transgene expression in vivo. Taken together, these findings suggest liposome as the best choice of TAs, which should be used in combination with rAAV-mediated gene therapy.

The cell-based approach in neurosurgery: ongoing trends and future perspectives

“…The virus-mediated insertion of foreign DNA into a target cell ultimately creates chimeric products which are able to perform a tailored interaction with their targets therefore fulfilling the therapeutic action. Although viral transduction techniques have been the most frequently employed gene carriers, plasmid transfection techniques involving liposome nanoparticle-mediated delivery of circular DNA, have also been recently reported [137, 138, 139, 140]. Gene modification technologies have been widely employed in hematology [141, 142, 143], oncology [14, 144, 145, 146], and more recently in neurology, as well [147, 148, 149].…”

Liposomes as Multifunctional Nano-Carriers for Medicinal Natural Products

“…Liposome not only delivers nature products but also biomacromolecules, such as DNA ( Guo et al, 2018 ), RNA ( Hou et al, 2021 ), protein ( Swaminathan and Ehrhardt, 2012 ), and bacteriophages ( Nieth et al, 2015 ) for therapies. Therefore, it is the potential to improve the therapeutic effects by combined therapy in cooperation with various drugs based on different mechanisms.…”